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ABSTRACT
Colonoscopy should be delivered by endoscopists
performing high quality procedures. The British Society of
Gastroenterology, the UK Joint Advisory Group on GI
Endoscopy, and the Association of Coloproctology of
Great Britain and Ireland have developed quality
assurance measures and key performance indicators for
the delivery of colonoscopy within the UK. This
document sets minimal standards for delivery of
procedures along with aspirational targets that all
endoscopists should aim for.
INTRODUCTION
Colonoscopy is the ‘gold standard’ investigation for
assessment of the large bowel, allowing diagnosis,
biopsying, and therapy to be undertaken. Colonoscopy
detects and prevents colorectal cancer,1 and is im-
portant in the diagnosis and treatment of non-
neoplastic conditions. Colonoscopy can lead to rare
but serious complications2–5 and poor quality col-
onoscopy is associated with increased rates of inter-
val cancers.6 The quality of UK colonoscopy has
improved over recent years,7 8 but unacceptable
variation in practice still exists.8 9 Additionally the
demand for colonoscopy is increasing.10–13
In 2013, the Joint Advisory Group on GI
Endoscopy ( JAG), the British Society of
Gastroenterology (BSG), and the Association of
Coloproctology of Great Britain and Ireland
(ACPGBI) commissioned a working group to
review existing and define new quality assurance
(QA) measures and key performance indicators
(KPI) for colonoscopy. The three governing bodies
nominated members of the working group who
authored the paper. Working group members took
responsibility for groups of standards and under-
took a review of existing literature, existing stan-
dards, and evidence for those standards. Where
evidence was available it was used to frame the
standards. Where no clear evidence existed then
existing standards and the expert opinion of the
working group were used to arrive at agreed stan-
dards. The standards were reviewed and amended
by the governing groups of the JAG, BSG and
ACPGBI and then further edited by the authors.
The document concentrates on the agreed stan-
dards and considers why a particular standard was
agreed.
This document establishes clear minimal standards
for KPI and QA measures. Where practice falls below
these levels then interventions are required to raise
the performance of those colonoscopists. Where the
authors believed that higher standards would be ideal
an aspirational target was set. The authors believe
that this is the level that all colonoscopists should be
aiming for to provide high quality practice.
CAECAL INTUBATION RATE
Minimal unadjusted caecal intubation 90%.
Colonoscopists should aspire to achieve 95%
unadjusted caecal intubation.
Photographic documentation of caecal intubation
should be obtained with images taken of clear
caecal landmarks or of terminal ileum.
It is important to examine the whole colon, but
practice is variable.7 14 15 The consequences of an
incomplete examination are missed diagnosis and
failure to prevent interval cancers.16 17 In a British
Society of Gastroenterology (BSG) audit of all colon-
oscopies performed within the UK over a 2 week
period,8 the unadjusted caecal intubation rate (CIR)
was 92.3% rising to 95.8% following adjustment for
impassable strictures and poor bowel preparation. A
further UK study9 demonstrated an unadjusted CIR at
92.5% (95% CI 91.2% to 92.6%). The English
Bowel Cancer Screening Programme (BCSP) pub-
lished the results of the first 3 years of screening18
with an unadjusted CIR of 95.2% (range 76.2–
100%). Given the CIR is in excess of 90% for large
series, this unadjusted rate should be the minimal
standard. The BCSP demonstrates that a higher CIR
can be achieved in a large programme and a standard
of 95% unadjusted CIR should be aspired to.
ADENOMA DETECTION RATE
Minimal adenoma detection rate should be 15%.
Aspirational adenoma detection rate should be
20%.
Where polyp detection rate can be shown to be
accurate it may be used as a marker of ADR.
Thorough examination of the colonic mucosa is
crucial to maximise the effectiveness of colonos-
copy as a diagnostic test. The adenoma detection
rate (ADR) is the proportion of colonoscopies
where one or more adenomas are detected. The
ADR is the marker most commonly used for this
purpose. Lower ADRs are associated with higher
rates of interval cancers.6 19 Colonoscopists with
an ADR <20% had a hazard ratio for interval
cancer that was 10 times higher than colonoscopists
with an ADR >20%. A recent UK study
Rees CJ, et al. Gut 2016;65:1923–1929. doi:10.1136/gutjnl-2016-312044 1923
Guidelines
 o
n
 23 January 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2016-312044 on 16 August 2016. Downloaded from 
demonstrated wide variation in ADR with a global ADR
(excluding screening colonoscopy) of 15.9%.9
ADR will vary according to the nature of the population colo-
noscoped and the indication for the procedure. However, even
allowing for variation in population ADR, the current 10% UK
minimum is too low. The 20% ADR reported by Kaminski
et al6 is aspirational, but was for a screening age population.
Therefore for the UK all age population a standard of 15% has
been set with an aspirational target of 20%.
Measuring ADR currently requires interrogation of pathology
databases to obtain polyp histology. The polyp detection rate
(PDR) is often much more simple to obtain. ADR is the key per-
formance measure but where it can be demonstrated that a ratio
between an endoscopist’s PDR and ADR has been developed and
validated, then PDR may be an acceptable surrogate marker20–22
with the minimum value set to ensure an ADR of 15% (20%
aspiration) is achieved. It is recommended that review of the val-
idity of PDR to represent ADR is audited on an ongoing basis.
Quality indicator Minimal standard Aspirational target Comment
Caecal intubation rate (CIR) (unadjusted) 90% 95% Photographic proof of ileocaecal valve, terminal ileum, anastomosis or
appendix orifice required in all cases
Adenoma detection rate (ADR) in general all
patient population (not screening)
15% 20% ADR is the quality standard. Given the difficulty in reporting ADR then
polyp detection rate or polypectomy rate may be used where it has
been demonstrated to reflect accurately ADR for that unit/clinician
Bowel preparation of sufficient diagnostic
quality to not warrant repeat or alternative
test
90% 95%
Rectal retroversion rate 90%
Colonoscopy withdrawal time (for negative
procedures)
Mean of 6 min Mean of 10 min
Sedation level for age <70
Median total dose:
50 mg pethidine (100 μg fentanyl)
5 mg midazolam (or equivalent drugs)
Auditable outcome
Sedation level
for age 70
Median total dose:
25 mg pethidine (50 μg fentanyl)
2 mg midazolam (or equivalent drugs)
Auditable outcome
Number of colonoscopies undertaken by
endoscopist (or directly supervising trainee in
room) per year
100 If numbers <150 then other key performance indicators, eg, CIR and
ADR, should be scrutinised more closely and, if concerns, action taken
Polyp retrieval rate 90%
Tattooing of all lesions 20 mm and/or
suspicious of cancer outside of rectum and
caecum
Tattoo placed in
100% of cases
Tattoo according to trust policy
Diagnostic biopsies for unexplained diarrhoea Rectal biopsies
taken in 100% of
cases
Right and left colonic
biopsies taken in 100% of
cases
Aspiration should be that a minimum of two right and two left colon
biopsies should be taken, but as minimum standard rectal biopsies
should always be taken (unless there is a contraindication)
Post-colonoscopy colorectal cancer Auditable outcome All post-colonoscopy colorectal cancers diagnosed within 3 years of a
colonoscopy should be reported as adverse events and each unit
should have a policy for capturing post-colonoscopy colorectal cancer
data
Comfort level Auditable outcome Units should audit this and <10% of patients should have moderate or
severe discomfort
Overall colonoscopic perforation rate <1 in 1000 <1 in 3000
Diagnostic colonoscopic perforation rate <1 in 2000 <1 in 4000
Colonoscopic perforation rate where
polypectomy performed
<1 in 500 <1 in 1500
Colonoscopic perforation rate where dilatation
performed
<3% (<1 in 33) <1% (<1 in 100)
Diagnostic flexible sigmoidoscopy (FS)
perforation rate
<1 in 5000 <1 in 10 000
Colorectal stenting perforation rate <10% <5%
Post-polypectomy bleeding rate (intermediate
severity or higher)
<1 in 200 <1 in 1000
Unplanned admission rate Auditable outcome;
review every case
Use of reversal agents Auditable outcome;
review every case
Auditable outcome—endoscopy units should audit these measures.
Additional recommendations
Management of polyps—all units should have a policy for management of polyps including a policy for dealing with large and large sessile polyps.
Tattoo policy—all units should have a policy for tattooing of polyps and cancers and should audit whether this is being followed.
Rectal examination should be performed at colonoscopy or before endoscopy. All units should audit practice.
Terminal ileal intubation—all units should audit practice and agree local policy.
1924 Rees CJ, et al. Gut 2016;65:1923–1929. doi:10.1136/gutjnl-2016-312044
Guidelines
 o
n
 23 January 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2016-312044 on 16 August 2016. Downloaded from 
BOWEL PREPARATION
Bowel preparation of at least adequate quality to be achieved
in 90% of patients.
Aspirational: bowel preparation of at least adequate quality to
be achieved in 95% of patients.
Aspirational: easy to use, validated national bowel preparation
scale should be developed.
High quality colonoscopy cannot occur without good quality
bowel preparation, which maximises CIRs and the detection of
neoplasia. This is highlighted by the 2013 ESGE position state-
ment23 issued to guide European countries setting up bowel
cancer screening services. Evidence in the UK shows that 22%
of failed colonoscopies were due to poor bowel preparation.8
There is a lack of evidence for one superior bowel cleansing
agent,23 therefore units should select their preferred agent based
on local experience and BSG guidance.24
At least five validated bowel preparation evaluation scales
exist;25–29 however, all involve relatively complex scoring
systems and are not in common usage in the UK. The BCSP
uses a four point scale: excellent, adequate, complete despite
poor preparation, or failed due to poor preparation.30 Despite
the subjectivity of this scale we recommend this or a similar
scale is recorded for all colonoscopies.
The minimum proposed CIR is 90%, and audit suggesting
that excellent or adequate bowel preparation can be achieved by
the BCSP in 94.2% of patients18 means that we recommend
bowel preparation be excellent or adequate in at least 90% of
patients, and in line with an aspirational CIR of 95%, would
have an aspirational standard of 95%.
We also have an aspiration to see validation of the BCSP scale
or a similar easy-to-use tool to become the UK standard bowel
preparation scale.
RECTAL EXAMINATION AND RECTAL RETROFLEXION
Rectal examination or omission should be recorded in 100% of
cases.
Rectal retroflexion should be performed in 90% of cases.
Digital rectal examination
Digital rectal examination (DRE) has been recommended as a
standard part of endoscopic examination of the lower gastro-
intestinal tract with the aim of preparing the anal canal for the
insertion of the scope and to examine the anal canal and lower
rectum for pathology.31 A comparison of DRE and rectal retro-
flexion showed that DRE was sensitive for detection of abnor-
malities in the lower rectum and upper anal canal that were
subsequently demonstrated on retroflexion of the endoscope.32
Rectal retroflexion
A number of studies have demonstrated increased detection of
pathology by using retroflexion after standard views of the
rectum have been obtained. An increase in yield of 8% was
demonstrated in one study,33 with others demonstrating a yield
of around 2–2.5%.34–37 Manoeuvre success rates between
94%36 and 100%38 have been reported. Retroversion may
rarely cause rectal injury39 40 with the estimated the risk
0.01%.41 We recommend that digital rectal examination and
retroflexion are attempted in all cases.
COLONOSCOPY WITHDRAWAL TIME
Minimum mean withdrawal time of 6 min for negative
procedures.
Aspirational: mean withdrawal time of 10 min for negative
procedures.
Withdrawal times should be routinely recorded and audited.
Colonoscopy withdrawal times (CWTs) of >6 min for nega-
tive procedures have frequently been linked to higher ADR,42
with the suggestion that longer times are beneficial,43 44 and an
increased ADR for trainees when the CWTwas over 10 min.45
An increased withdrawal time may also be associated with
improved technique such as position change, better aspiration of
fluid pools, and more attention to deep folds and difficult
corners.46 Other studies, however, have not shown a link
between CWT and polyp detection using the cut-off of 6 min47
or 7 min.48
Mean withdrawal times for negative procedures should be
more than 6 min with an aspirational goal of achieving 10 min.
This KPI should be linked to the ADR or PDR such that a low
CWT with a low ADR strongly suggests inadequate technique
(in the absence of other explanations such as population group)
that requires managed changes in performance.
SEDATION
Sedation level for age <70: median total dose 50 mg pethid-
ine (100 μg fentanyl), 5 mg midazolam or equivalent drugs.
Sedation level for age 70: median total dose 25 mg pethid-
ine (50 μg fentanyl), 2 mg midazolam or equivalent drugs.
In the UK, the majority of colonoscopies are performed
under conscious sedation. These standards are based upon the
current BSG sedation guidelines.49 The recent BSG audit
reported >90% of sedation practice was in line with these
guidelines. More than 10% of procedures were performed
without sedation, with nitrous oxide used as the sole sedative
agent in 4.2% of procedures. Reversal agents were required in
only 0.1% of procedures. Similar sedation practice was reported
in a large regional study,50 with 85.6% of procedures performed
under conscious sedation. These data suggest that conscious sed-
ation can be performed safely and it appears to be satisfactory
in the majority of cases, accepting the limitations of current
methods of measuring comfort. Current sedation standards
should be maintained.
NUMBER OF COLONOSCOPIES PERFORMED PER ANNUM
Minimum number colonoscopies to achieve competence: 200.
Minimum numbers per annum to maintain competence: 100.
Achieving competency
Accepting that CIR is usually self-reported, the literature reports
a number of studies that evaluate how many procedures are
required to consistently reach a CIR of 90%. Current UK stan-
dards require at least 200 procedures to achieve competency,
strengthened with a publication51 showing competency (based
on a CIR of 90%) is reached by 41% of trainees after 200 pro-
cedures. Similar figures of between 175 and 400 have been
quoted, with the average trainee requiring 275 procedures.52–54
Although a numbers-based approach is easy to document, a
broader evaluation is recommended by most learned societies.
Maintaining competency
A few studies point to a figure of at least 100 procedures per
annum in order to maintain competency (ie, a CIR of
90%).55 56 Other studies have suggested a higher procedural
volume of 200–300 may be necessary to maintain competent
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and safe practice with figures below that being associated with
lower CIR56 and higher complication rates.5 Other markers of
competence such as ADR do not appear to correlate well with
procedural numbers.57
POLYP RETRIEVAL
Polyps should be retrieved for histological assessment in 90% of
cases.
Following successful polyp removal it is important to
retrieve it for histological assessment. This is important to
establish the histological nature of the polyp to determine sur-
veillance intervals and to establish the presence of advanced
features such as high-grade dysplasia, villous components or
cancer. Polyps whose diameter is <1 cm are less likely to
contain these features; however, retrieval is still important to
determine whether there are adenomatous features that deter-
mine the need for surveillance. Polyp retrieval is also consid-
ered a reflection of the technical skill of the colonoscopist. No
evidence correlating polyp retrieval rates with other markers
of quality exists. We recommended polyp retrieval rates should
be 90% in the UK.
TATTOOING OF SUSPECTED MALIGNANT LESIONS IN THE
COLON
Tattooing of all lesions 20 mm and/or suspicious of cancer
outside of the rectum and caecum should take place in 100% of
cases following local trust guidance.
Tattooing aids the accurate marking of suspected malignant
lesions and resection sites, to guide future surgical resection
and/or endoscopic surveillance. This technique58 has been
shown to guide surgical resections safely and accurately.59
As polyps increase in size the risk that they harbour cancer
increases. All polyps >2 cm in diameter should be marked by
tattoo. Lesions <2 cm in diameter should be assessed by careful
inspection and marked if they have high risk features as
described in the guidelines of the BCSP.60
There should be a clear local policy agreed by the colorectal
multidisciplinary team meeting (MDT) defining the number of
tattoos and their site relative to the lesion so that there is no
ambiguity at the time of surgery or repeat endoscopy. The
report should clearly describe the position of tattoos and high-
light any potential for confusion if there is more than one set of
tattoos in the colon.
DIAGNOSTIC BIOPSIES FOR UNEXPLAINED DIARRHOEA
100% of patients with unexplained diarrhoea to have rectal
biopsies.
As an aspiration 100% of patients with unexplained diarrhoea
undergoing colonoscopy to have right and left sided colonic
biopsies.
A macroscopically normal examination does not exclude all
causes of unexplained diarrhoea,61 with the most common diag-
nosis being microscopic colitis. Microscopic colitis can be
patchy and biopsies from both the right and transverse colon
are required for diagnosis,62–65 a practice reinforced by the
American Society for Gastrointestinal Endoscopy (ASGE) guide-
lines.66 We recommend that, unless there is a contraindication,
the minimum standard remains that 100% of patients with
unexplained diarrhoea should have rectal biopsies performed.
As an aspiration, 100% of patients undergoing colonoscopy to
investigate unexplained diarrhoea should have right and left
sided colonic biopsies.
POST-COLONOSCOPY COLORECTAL CANCER RATE
All units should develop a system for capturing data on and
reviewing each case of post-colonoscopy colorectal cancer
(PCCRC) as a clinical incident subject to root cause analysis.
Units should aspire to a target of <5% PCCRC at 3 years.
There is wide variation in the PCCRC rate from 0% at mean
of 5 years67 to 9%.68 Some of this may derive from study
design—especially data origin, exclusion criteria and population
studied, and from method of calculation used. A recent study69
in England between 2001 and 2008 looking at National Cancer
Data Repository information and central procedural data shows
an 8.5% overall PCCRC rate for colonoscopies performed
between those dates, although the rate fell over time from
10.6% to 6.8%.
Colonoscopists with high adenoma detection and polypect-
omy rates provide increased protection for proximal cancers
compared with those with lower polypectomy rates.68 Specialty
and volume of examinations performed have an influence on
interval cancer rates.17 70 A landmark paper in the New
England Journal of Medicine6 demonstrated that mucosal visual-
isation and adenoma detection influence the rate of future
cancers.
Polypectomy technique also influences PCCRC, with incom-
plete polypectomy71 contributing to later interval cancers.
Pooled North American post-polypectomy studies72 demon-
strated missed cancer contributing 52% to the interval cancer
rate, with 19% possibly due to incomplete polyp resection. A
further study73 found 27% of interval cancers developed in the
same segment as a previous polypectomy, indicating incomplete
treatment may have been a contributory factor. Particular
emphasis should be placed upon detection of easily missed
lesions such as flat, depressed and serrated lesions, particularly
in the proximal colon.74 75
COMFORT
Units should audit comfort and <10% of patients should have
moderate or severe discomfort.
Patient experience of colonoscopy is important and patients
should have as comfortable a procedure as possible. A national
audit8 demonstrated that 10% of patients experienced moderate
or severe discomfort. Although measuring comfort is difficult, a
number of scoring systems exist and all units should consistently
record patient comfort. Validated measures of patient comfort
should be developed.
ADVERSE EVENTS
Colonoscopy is an invasive procedure, which carries a risk of
bleeding, perforation and even death. Although the risk is
small with diagnostic colonoscopy, it increases markedly
when therapeutic procedures such as polypectomy are per-
formed. It is important that endoscopy units develop QA
approaches to investigate adverse events and consider the fre-
quency with which these events might be expected (tables 1–
3, box 1).
Perforation
The overall colonoscopic perforation rate is influenced by the pro-
portion of diagnostic to therapeutic procedures performed. In four
recent large series overall perforation rates ranged from 0.03% to
0.085%.2–5 A recent review of studies calculated an overall perfor-
ation rate of 0.07%.76 The BSG audit8 demonstrated an overall
perforation rate of 0.04%. For diagnostic colonoscopy perforation
rates of 0–0.2% are reported.77–79 The two main risk factors for
1926 Rees CJ, et al. Gut 2016;65:1923–1929. doi:10.1136/gutjnl-2016-312044
Guidelines
 o
n
 23 January 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2016-312044 on 16 August 2016. Downloaded from 
post-polypectomy perforation are the size and proximal (caecal)
location of polyps.79 Two small series reported polypectomy per-
foration rates of 0.65% and 0.27%, whereas two slightly larger
retrospective series reported rates of 0.11% and 0.06%.80–83 The
recent review of studies calculated the perforation rate in thera-
peutic colonoscopy to be 0.1%,76 in keeping with the BCSP per-
foration rate in polypectomy procedures of 0.09%.79
Bleeding
The risk of post-procedure bleeding is very small with diagnostic
colonoscopy, but increases markedly when polypectomy is per-
formed. The two main risk factors are the size and proximal
(caecal) location of polyps.79 81 Other reported risk factors
include co-morbid cardiovascular or chronic renal disease,84
age,84–86 anticoagulant use84 85 and endoscopist experience.85
Studies assessing the effect of polyp morphology are inconclu-
sive.79 86 87 Bleeding rates of 0.3–6.1% for polypectomies are
reported.77 85 The recent UK audit reported a bleeding rate of
0.26%.8 A recent large series reported a colonoscopy bleeding
rate of 0.164%.5 BCSP data illustrate the importance of stratify-
ing bleeding severity: in one study the overall bleeding rate
(including many clinically insignificant bleeds) was calculated as
0.59%; limiting the analysis to intermediate or major severity
bleeds (haemoglobin drop of 2 g, transfusion, ITU admission,
unplanned hospital admission for four or more nights, interven-
tional radiology or endoscopy, or surgery), the rate was
0.13%;18 and limiting only to bleeding requiring transfusion,
the rate was 0.04%.79 We recommend that standardised severity
stratification systems are used.88
CONCLUSION
The agreed QA measures and KPI should be implemented across
the UK. Individual endoscopy units are responsible for measuring
and acting upon the standards. The JAG will monitor adherence
to these standards. Where performance falls below the standards
then units should explore and understand underperformance and
measures to improve performance should be instituted.
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